BioSpace News Archive

St. Jude Children’s Research Hospital has acquired the first Ascend 1.1 GHz Nuclear Magnetic Resonance Spectrometer, the largest and most powerful device of its kind from Massachusetts-based Bruker Corp.

With today’s launch of the open comment period for the draft “Biomarker Testing for the Diagnosis of Diffuse Gliomas” evidence-based guideline, the College of American Pathologists (CAP) joins forces across the clinical care team to improve how adult and pediatric patients with these tumors are diagnosed and treated.

Aurora Cannabis Inc. (“Aurora or the “Company”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, is pleased to announce that it has closed its previously announced amended and upsized credit facilities with a syndicate of lenders led by the Bank of Montreal (“BMO”)

Nano Discovery Inc. announced today that it has launched a new blood test to the market for cattle immune health testing.

IRBM today announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center.

TEDAN SURGICAL INNOVATIONS LLC. (TSI), leader in the development and commercialization of surgical access systems furthers its commitment to surgical access innovation through the market release of its UltraFix™ Stabilization technology as part of the second-generation, Phantom XL3™ Lateral Lumbar Surgical Access platform.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced it will present for the first time initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking poster presentation at the 35thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced that it has licensed a sixth gene therapy development program under its research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP).

Willow Biosciences Inc. announces that, pursuant to the terms and conditions of its stock option plan, it has granted an aggregate of 1,118,000 stock options to purchase common shares of Willow to certain employees.

Aon plc (NYSE:AON), the leading global professional services firm providing a broad range of risk, retirement and health solutions, has announced the evolution of its Investor Relations team